3 unknown, 2 recruiting, 1 active not recruiting, 1 completed. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Unknown 3, Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 4 | Unknown 3, Recruiting 1 |
Follow Transformed Lymphoma: new trials by email Literature Review of Transformed Lymphoma trials Research Report on Transformed Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Acalabrutinib - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 24 | 2023-01-23 | 2026-03-10 |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma Mosunetuzumab - B Cell Lymphoma, Aggressive Lymphoma | Phase 1 | Active not recruiting | Washington University School of Medicine | 9 | 2022-12-22 | 2026-10-13 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells - Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | Recruiting | C. Babis Andreadis | 36 | 2020-09-11 | 2026-10-26 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma BZ019 - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 12 | 2018-06-08 | 2026-02-11 |
Lymphoma, Large B-Cell, Diffuse (6) · Pyloric Stenosis, Hypertrophic (3) · Lymphoma, Follicular (2) · Recurrence (2) · Burkitt Lymphoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · Digestive System Diseases (3) · Disease Attributes (3) · Gastric Outlet Obstruction (3) · Gastrointestinal Diseases (3) · Pathologic Processes (3)
Automobiles (1) · Cyclophosphamide (1) · Immunotherapy, Adoptive (1) · Lenalidomide (1) · R-CHOP protocol (1) · Rituximab (1) · Therapeutics (1) · acalabrutinib (1) · apatinib (1) · camrelizumab (1) · fludarabine (1) · fludarabine phosphate (1) · spartalizumab (1) · tislelizumab (1) · toripalimab (1)
Huiqiang Huang (3) · C. Babis Andreadis (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jonsson Comprehensive Cancer Center (1) · Washington University School of Medicine (1)
China (4) · United States (3)
Armin Ghobadi, M.D. (1) · Carrie Ho, MD (1) · Caspian Oliai, MD (1) · Huiqiang Huang, Professor (1) · Lugui Qiu, MD (1)